The CoopERA BC study compared the efficacy and safety of neoadjuvant giredestrant versus anastrozole plus palbociclib in the treatment of ER‐positive, HER2‐negative, postmenopausal early breast cancer. Here, ERBB2 is linked to breast cancer.